Introduction {#s1}
============

Radio-epidemiological studies provide evidence that exposure to ionizing radiation is especially harmful during childhood. Application for diagnostic or therapeutic purposes can cause diseases such as leukemia or solid cancers of the brain, breast or thyroid even decades after exposure ([@CIT0001]). Strongest evidence for the statistical association between radiation exposure and thyroid cancer has been produced by studies of children and adolescents who ingested radio-iodine from fallout of the Chernobyl accident in April 1986. Early studies were published about a decade after the event and have already reported a marked increase of the radiation risk \[reviewed in ([@CIT0004],[@CIT0005])\]. In later studies on about 13000 subjects of the Ukrainian-American (UkrAm) cohort, which were exposed below 19 years and were put under enhanced medical surveillance since 1998, the excess relative risk (ERR) per thyroid dose dropped from about 5 per Gy for mean age at operation (AaO) 16 years to just below 2 per Gy for mean AaO 24 years ([@CIT0006],[@CIT0007]). The estimate for a similar cohort from Belarus is compatible with this decreasing trend of attained age ([@CIT0008]). For exposure in adulthood, the risk in Japanese a-bomb survivors is just marginally elevated ([@CIT0009]).

Although conventional radio-epidemiological analysis is the method of choice to determine the dose--response relationship for a given disease, limitations of this approach become increasingly obvious. Statistical power can be improved by pooling of cohorts but uncertainties on dose estimates and other co-factors are accumulated as well ([@CIT0010]). The accuracy of risk estimates even from studies with thousands of cases might not be sufficient to decide if radiation is causing detrimental health effects at doses below about 100 mGy ([@CIT0011]).

Molecular biomarkers of ionizing radiation are being searched intensively to separate radiation-induced cancer cases from sporadic cases with greater accuracy than can be gained from epidemiology ([@CIT0012]). But to date, many such attempts lack a satisfactory justification because mechanisms that relate radiation to carcinogenic processes on a molecular level are still not fully explained ([@CIT0013]). Based on integrative systems biology, the search for a molecular biomarker of a disease caused by radiation is probably most advanced in thyroid carcinogenesis. The histological composition of more than 90% of all thyroid carcinoma from the Chernobyl studies pertains to papillary thyroid cancers (PTC). Genomic analysis of PTC samples stored in the Chernobyl tissue bank (CTB, [www.chernobyltissuebank.com](www.chernobyltissuebank.com)) revealed a DNA copy number gain on chromosome band 7q11.23 and mRNA overexpression of the CLIP2 gene related to radiation exposure ([@CIT0014]). The samples came from the Genrisk-T cohort of patients which were exposed at very young age below 5 years. Radiation-related CLIP2 overexpression has been validated with independent samples from cohorts Genrisk-T and UkrAm at protein level using a dedicated protocol which combined immunohistochemistry with digital image analysis ([@CIT0015]). Results from both studies suggest that CLIP2 overexpression can be applied as a dichotomous biomarker to decide on the sporadic or radiation-associated origin of a PTC in young patients operated below 20 years ([@CIT0016]).

The strategic aim of the EU-funded EpiRadBio project was to improve risk assessment at low doses by benefiting from molecular measurements in cancer tissue from patients who were also members of radio-epidemiological cohorts. This aim is addressed here with a multiscale approach of modeling which comprises data over several length orders from point mutations to cells and tumors ([@CIT0017]). It enables us to relate the CLIP2 findings to the radiation risk of the UkrAm cohort and to explore the impact of radiation on molecular alterations such as mutations, genomic copy number alterations (CNAs) or altered mRNA and protein expression ([@CIT0018]).

To harness molecular data as hallmarks of key carcinogenic processes for risk assessment, we apply mechanistic models. Simple versions of such models have been developed in the 1980s and have later been couched in a general mathematical framework ([@CIT0019],[@CIT0020]). They already treated carcinogenesis as a progression of cell-based events at yearly rates such as mutations on the pathway to cancer. But the success of mechanistic models remained limited since the association of model parameters with well-defined molecular changes appeared rather vague. Growing insight into molecular processes has been gained from numerous omics technologies. It now offers a more tangible characterization of the stages which are featured in a mechanistic model. Beneath mutations in driver genes they comprise a wider range of phenomena such as gene rearrangements or fusions and even chromosomal instabilities (gains and losses of chromosomes or chromosome arms) ([@CIT0021],[@CIT0022]). Clonal growth of pre-cancerous lesions from cells which have accumulated initial genetic damage could also influence the incidence data. As general condition, molecular events must be rate-limiting to be detectable in cancer incidence data. As example, the model of radiation-induced colon cancer in Japanese a-bomb survivors includes already a number of such rate-limiting events ([@CIT0023]).

In this work, we investigate whether CLIP2 overexpression constitutes a reliable radiation marker which can improve risk assessment. Using mechanistic modeling as a tool, we present a characterization of clinical and molecular properties associated with sporadic and radiation-induced PTC.

Materials and methods {#s2}
=====================

Data sets {#s3}
---------

### UkrAm cohort for radiation epidemiology {#s4}

Scientific aims, design and risk assessment for the UkrAm cohort are already presented in previous studies ([@CIT0006],[@CIT0007]). The cohort data was gathered in the Ukraine during four screening cycles between 1998 and 2008. Previous analyses were performed with either 45 prevalent cases of the first screening cycle ([@CIT0006]) or 65 incidental cases of the second to fourth screening cycles ([@CIT0007]). In those studies, all histological types of papillary, follicular and medullary thyroid cancer were combined for the main risk analysis. This study is only concerned with development of PTC. To achieve maximal statistical power, all 115 PTC cases were included which have been operated in the UkrAm cohort until 2008. The buildup of the cohort data for the present study is given in the [Supplementary Material](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online. A breakdown of thyroid cancer cases with their use in previous studies compared to this study is shown in [Supplementary Table 1](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online. The data set of 13183 subjects for this study is summarized in [Supplementary Table 2](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online. We applied the same individual dose estimates from dosimetry system TDose10 ([@CIT0024]) as Brenner *et al.* ([@CIT0007]). Model development and risk analysis has been performed with fits to the UkrAm cohort.

### Tumor cohort for molecular biology {#s5}

In contrast to the above-mentioned epidemiological UkrAm cohort, our tumor cohort of 141 PTC patients from the CTB with individual CLIP2 status and TDose10 estimates ([@CIT0027]) has been formed previously by Selmansberger *et al.* ([@CIT0016]). They have joined the discovery cohort Genrisk-T with validation cohorts Genrisk-T plus and UkrAm (CTB tumors only) which were investigated in earlier exploratory studies related to the CLIP2 marker ([@CIT0014],[@CIT0015]). All PTC cases are listed in Table. Seventy of our 141 cases from the CTB also belonged to the epidemiological UkrAm cohort. Most of the young patients with AaO \< 20 years (63 out of 76) pertained to cohorts Genrisk-T and Genrisk-T plus. Both cohorts also contained 24 patients with AaO \< 20 years and nominal doses of 1 mGy/year who were born after 1986. Parameters of the mechanistic model were determined by fits to the epidemiological UkrAm cohort. But model results on the prediction of the CLIP status have been validated with our tumor cohort. For subsets of the tumor cohort, measurements on various molecular alterations have been performed ([@CIT0018]). The impact of radiation on these alterations has been investigated with the mechanistic model.

###### 

Number of PTC cases with CLIP2 status in the tumor cohort of this study, which was formed by Selmansberger *et al.* (16) (see their Supplementary Table 1), number of PTC cases in the epidemiological UkrAm cohort of this study (cases without CLIP2 typing in brackets) and number PTC cases with CLIP2 typing; which belong to both cohorts, divided in groups of AaO before and after 20 years

  AaO Period        Tumor cohort Mean AaO (years)   Cases   Cases common In both cohorts   Epidemiological UkrAm cohort
  ----------------- ------------------------------- ------- ------------------------------ ------------------------------
  AaO ≥ 20 years    27.7                            65      56^a^                          86 (30)
  AaO \< 20 years   16.6                            76^b^   14^c^                          29 (15)
  All AaO           21.7                            141     70                             115 (45)

^a^Three patients with AaO ≥ 20 years were members of the UkrAm cohort according to information from the CTB; but were not present in the epidemiological UkrAm cohort of this study.

^b^Including 24 patients with nominal doses of 1 mGy/year born after 1986 from Genrisk-T cohort.

^c^One patient with AaO \< 20 years from cohort Genrisk-T was member of the epidemiological UkrAm cohort.

Mechanistic model of PTC pathogenesis {#s6}
-------------------------------------

### Biological basics of thyroid carcinogenesis {#s7}

The human thyroid contains about 10^10^ follicular cells (thyrocytes) ([@CIT0028]). Among them about 0.1% somatic stem cells might be susceptible to cancer development ([@CIT0029]). Molecular and functional properties of somatic stem cells are largely unknown because they are rare and difficult to identify ([@CIT0030]). The adult thyroid gland is a slowly proliferating organ with a turnover rate of 8.5--14.4 years in order to maintain its size and function ([@CIT0031]). PTC is the most common histological type of thyroid cancer. According to the paradigm of multistage carcinogenesis (MSC), PTCs develop from unknown precursor cells deriving from normal thyrocytes by acquiring genomic instability ([@CIT0032]). Rearrangements of the RET gene (RET/PTC) are frequent alterations in PTCs ([@CIT0033],[@CIT0034]). However, their association with radiation exposure is not well established ([@CIT0035]). Point mutations of the BRAF gene and RAS mutations are both mutually exclusive but occur mainly in sporadic PTC ([@CIT0018],[@CIT0036]). Both mutations lead to a deregulated MAPK pathway. Furthermore, CNAs are frequently reported in PTCs and might be considered as hallmarks of MSC ([@CIT0018],[@CIT0032]).

The oncogenic processes leading to PTC development are not fully understood. We assume that CLIP2 overexpression is an early event predominantly in radiation-related PTC development. A functional network analysis of the CLIP2 gene revealed associations with genes involved in both MAPK signaling and genomic instability ([@CIT0015]). By triggering RET/PTC rearrangements, CLIP2 overexpression may represent a driver event but a mere passenger event cannot be excluded. Compared to MSC we expect to find a lower number of CNAs in CLIP-related carcinogenesis (CSC) which also involves fewer genes ([@CIT0014],[@CIT0036]). During a comparatively short latency period of less than 17 years from exposure at very young age (\< 5 years) to surgery precancerous cells do not develop much differentiation.

Takano ([@CIT0039]) has argued against the role of MSC in PTC development after Chernobyl because thyrocytes rarely proliferate. Neither are intermediate cells known, nor have morphological precursor lesions been detected. PTC appeared most frequently in patients exposed at very young age assuming that thyroblasts are still present as potential radiation targets. The disappearance of thyroblasts in older subjects therefore leads to a reduced radiation sensitivity of the thyroid gland. But the form of an age-dependent decay function for thyroblasts is not known. Takano's ([@CIT0039]) notion of pathogenesis for post-Chernobyl PTC is represented by the molecular changes related to CLIP2-related carcinogenesis (C2C).

### Conceptual model {#s8}

We can now construct a mechanistic model which reconciles the determinant biological features of both MSC and C2C. Different molecular mechanisms in early PTC development imply a conceptual model design which relies on distinct pathways for the pathogenesis of sporadic PTC without the CLIP2 biomarker (MSC) compared to PTC with the CLIP2 biomarker (C2C). As a common feature both pathways include deregulated MAPK signaling albeit at different stages ([Figure 1](#F1){ref-type="fig"}). Our preferred mechanistic model consists of two submodels for MSC and C2C with separate mathematical formulations which are outlined in the [Supplementary Equations (1--12)](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online.

![Conceptual model for the development of sporadic PTC from multi-stage carcinogenesis (MSC) (upper path) and sporadic or radiation-induced PTC from CLIP2-associated carcinogenesis (C2C) (lower path), path-specific case shares are calculated from the preferred mechanistic model based on 141 PTC patients used in Selmansberger *et al.* ([@CIT0016]), a mathematical implementation of the model is given in the [Supplementary Material](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online, black arrows with Greek symbols denote transition rates between boxes, jagged yellow arrow denotes radiation action on rate µ, boxes represent cells with molecular changes discussed in Selmansberger *et al.* ([@CIT0018]) for (**a**) point mutations of genes BRAF, RAS or gene rearrangements (e.g. RET/PTC) ([Supplementary Table 10](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online), (**b**) copy number alterations (MSC) or CLIP2-associated aneuploidy ([Supplementary Table 9](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online), (**c**) transcriptomic subtypes 'RAS-like', 'intermediate RAS-BRAF', 'BRAF-like' ([Supplementary Table 10](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online) and (**d**) novel transcriptomic subtype (radiation-related) ([Supplementary Table 10](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online).](carcin_bgw102_f0001){#F1}

The MSC submodel for sporadic PTC without the CLIP2 marker starts with healthy thyrocytes. It involves two initiating mutations with rates ν~0~, ν~1~ followed by a phase of clonal expansion with net rate γ = α−β. It is inspired by similar models for cancers in the colon and thyroid ([@CIT0023],[@CIT0040],[@CIT0041]). The rates for symmetrical stem cell division α and inactivation (or differentiation) β of initiated cells cannot be identified from the incidence data but the net rate γ of clonal expansion can be estimated quite well. Formally, the process is concluded when at least one cell from the premalignant clones suffers a late transforming event which produces a non-extinct tumor stem cell ([@CIT0040]). This event with effective rate ν~2~ summarizes a series of complex processes in the late carcinogenic stage. The model for the MSC path reflects the pertinent hallmarks of cancer such as CNAs, mutations in driver genes and clonal expansion of precancerous lesions ([@CIT0021],[@CIT0022]). However, statistical support for the latter process appears rather weak in the model.

The C2C submodel for young patients (AaO \< 20 years) is based on a hypothesis by Takano ([@CIT0039]) who proposes a dedicated molecular path starting from fetal thyroid cells (or thyroblasts). A numerical value for the number *N* ~b~ of thyroblasts is difficult to estimate. In young patients, the CLIP2 marker is induced by radiation, whereas in a small number of older patients the CLIP2 marker appears also sporadically ([@CIT0016]). We assume that C2C occurs in a simple two-stage model with different parameter dependencies for radiation-induced C2C (rC2C) and sporadic C2C (sC2C). In the C2C submodel, two transitions (or mutational hits) with rates μ~0~, μ~1~ are required to produce a cancer cell. Radiation action increases the first hit μ~0~ for a short period to induce a permanently enhanced radiation risk after exposure. Sporadic PTCs within C2C are induced by a step-like increase of the second hit μ~1~ after age 20 years possibly due to altered cell interactions in the adult thyroid. This step is immediately reflected in the hazard for sC2C without delay.

Statistical analysis {#s9}
--------------------

To put goodness-of-fit and risk estimates of mechanistic models into perspective, descriptive risk models, which are based solely on statistical associations between exposure and disease, have also been applied to the epidemiological UkrAm cohort. The epidemiological analysis was performed with the MECAN software package where the risk models have been implemented ([@CIT0042]). Details on the form of the likelihood function, parameter estimation and uncertainty analysis are given in the [Supplementary Material](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online. Statistical analysis of the tumor cohort has been performed with the R package ([@CIT0043]).

Results {#s10}
=======

Preferred risk models {#s11}
---------------------

The preferred descriptive and mechanistic risk models have been selected from about 40 candidate models according to criteria of goodness-of-fit and biological plausibility. In [Supplementary Table 4](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online, deviance and number of adjusted model parameters are shown for a shortlist of candidate models. The preferred models accidentally produced the same deviance. To correct for unexplained variations in PTC incidence possibly related to iodine deficiency, the total risk for Zhytomir oblast has been adjusted for by a heuristic factor exp(Φ~obl86~). Model parameters are listed in [Supplementary Tables 5 and 6](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online.

Descriptive models of the excess absolute risk (EAR) yielded better fits than ERR models for the same adjustment for oblast. Thus, descriptive ERR estimates were calculated from the preferred EAR model described in [Supplementary Equation (13)](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* online.

For the preferred mechanistic model, the five adjustable parameters of the MSC and rC2C components were estimated by fits to the UkrAm cohort data ([Supplementary Table 5](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online). The three parameters of the sC2C model component were determined separately after the parameters for the rC2C and MSC components have been fitted by likelihood regression. They were adjusted to produce the expected 19 PTCs with the CLIP2 marker in 86 patients with AaO ≥ 20 years in the UkrAm cohort. The decomposition of the hazard function into the three components for MSC, rC2C and sC2C is shown in [Supplementary Figure 3](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online.

Validation with the CLIP2 marker {#s12}
--------------------------------

A pertinent link between molecular biology and radiation epidemiology is established by comparing the conditional probability *P* ~mol~(C2C\|PTC) of finding the CLIP2 marker in a PTC from molecular measurements with the epidemiological estimate *P* ~epi~(C2C\|PTC) of the same quantity. The construction of *P* ~epi~ from hazard functions of the preferred mechanistic model is given in the [Supplementary Equation (19)](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online. In radiation epidemiology, *P* ~epi~ is often termed probability of causation.

In [Figure 2](#F2){ref-type="fig"}, the estimate for *P* ~epi~ at attained age 17 years is compared with the response *P* ~mol~ for AaO \< 20 years of Selmansberger *et al.* ([@CIT0016]). For young patients, the probabilities exhibit similar dose responses in view of their uncertainties. Older patients do not possess a dose response so that in [Supplementary Figure 4](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online, only the crude rate of the positive CLIP2 marker among PTCs with AaO ≥ 20 years is indicated. For AaO ≥ 20 years, *P* ~epi~ shows an offset at zero dose which is caused by sporadic PTCs in the sC2C path.

![Dose response for the probability P(C2C\|PTC) of detecting a positive CLIP2 biomarker in a PTC case at attained age 17 years (mean age in group AaO \< 20 years) from mechanistic model (black line) compared to the dose response for from logistic regression on molecular measurements for AaO \< 20 years ([@CIT0016]) (red line); crude rates (blue points) from [Supplementary Table 7](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online.](carcin_bgw102_f0002){#F2}

To substantiate the visual impression of [Figure 2](#F2){ref-type="fig"} and [Supplementary Figure 4](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online, a comparison of measurements and model predictions on the CLIP status has been performed. The 141 PTCs from our tumor cohort were subdivided in three different dose groups for AaO \< 20 years and a single group for all PTCs with AaO ≥ 20 years combined ([Supplementary Table 7](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online). The predicted numbers of CLIP-positive cases were calculated with [Supplementary Equation (21)](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online. The 95% CI of the measured crude rate included the rate from model prediction in all four groups.

We present the same comparison for a subdivision of our 141 cases in the discovery cohort Genrisk-T and in validation cohorts Genrisk-T plus and UkrAm (CTB tumors only) ([@CIT0015]). In total the mechanistic model predicts 92/49 cases with CLIP2-positive/negative biomarker in compliance with measurements of 93/48 cases ([@CIT0016]). [Table 2](#T2){ref-type="table"} shows remarkable agreement between model predictions and measurements for AaO \< 20 years. Model predictions suggest for patients born after 1986 that even very low doses of background radiation cause PTC. For AaO ≥ 20 years the effect of the sC2C path appears which generated about 14 sporadic cases in addition to the 25 radiation-induced cases from the rC2C path.

###### 

Number of PTCs with positive CLIP2 marker among the 141 PTCs in our tumor cohort broken down by cohorts Genrisk-T, Genrisk-T plus and UkrAm (16), measurement results are compared with mechanistic model predictions, mean values of AaE, TsE, AaO and thyroid dose are given were applicable

  Cohort                   Arithmetic means   PTC cases with positive CLIP2 marker                              
  ------------------ ----- ------------------ -------------------------------------- ------ ------- ---- ------ ------
  Genrisk-T                                                                                                     
   Unexposed^a^      17    ---                ---                                    14.9   0.015   3    5.0    4.9
   Exposed           15    1.9                15.9                                   17.8   0.278   11   11.1   10.6
  Genrisk-T plus                                                                                                
   Unexposed^a^      7     ---                ---                                    15.3   0.015   3    2.0    1.9
   Exposed           30    2.2                15.5                                   17.8   0.750   23   23.0   22.2
  UkrAm patients                                                                                                
   AaO \< 20 years   13    2.2                15.6                                   17.8   1.558   10   11.5   11.4
  UkrAm patients                                                                                                
   AaO ≥ 20 years    59    9.4                17.9                                   27.3   1.175   43   39.0   25.4
   Total             141   ---                ---                                    17.0   0.577   93   91.5   76.4

^a^Unexposed patients are born after 1986 and are given a nominal dose of 1 mGy/year.

Risk assessment {#s13}
---------------

Risk estimates of this study are derived solely for PTC whereas other risk studies report mostly estimates for all histological types of thyroid cancer. This difference is negligible since PTC is the dominant type. [Supplementary Table 8](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online, presents estimates of the EAR and the ERR from the preferred mechanistic and descriptive models. They are almost identical for both models so that a separate discussion is not necessary.

### Excess absolute risk {#s14}

We found no dependence on attained age, age at exposure (AaE) or time since exposure (TsE) for estimates of the EAR in contrast to estimates for a-bomb survivors which show a marked increase for young AaE ([@CIT0009],[@CIT0011],[@CIT0044]). Up to 1 Gy, the dose response is nearly linear, for higher doses exponential attenuation sets in. The oblast-averaged point estimate for both sexes of 5.1 PTC cases per 10000 PY at 1 Gy in [Supplementary Table 8](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online, is a factor of 2--3 higher compared to estimates from studies for Chernobyl children and a-bomb survivors ([@CIT0007],[@CIT0009],[@CIT0044],[@CIT0045]). The reason for different estimates of the EAR from this study and of 1.7 (95% CI \< 0.06; 5.0) PTC cases per 10000 PY at 1 Gy from Brenner *et al.* ([@CIT0007]) is mainly related to their approach of oblast correction. This approach lowers the deviance by about 10 points compared to the approach of Ref ([@CIT0007]). Our EAR estimate agrees well with the estimate of 4.4 (95% CI 1.9; 10.1) cases per 10000 PY at 1 Gy from Ron *et al.* ([@CIT0046]).

### Excess relative risk {#s15}

[Figure 3](#F3){ref-type="fig"} shows that UkrAm estimates drop much faster than estimates from Japanese a-bomb survivors ([@CIT0044]). Such trends in the UkrAm cohort are likely to be influenced by screening effects. They seem to shorten the latency period of radiation-induced cases and increase the slope of the age dependence. Our point estimates of the ERR at age 27 years in [Supplementary Table 8](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online, are identical to those of Ref. ([@CIT0007]). Our confidence intervals are markedly narrower since they are derived from 115 PTCs compared to 61 PTCs in Ref. ([@CIT0007]). Our ERR estimates are similar to those of refs. ([@CIT0009],[@CIT0011],[@CIT0044]) at an attained age of 20 years. They drop fast according to age^−4^ whereas for older ages other studies ([@CIT0009],[@CIT0044]) report a substantial ERR of about 1 Gy^−1^ even decades after exposure below age 10 years. The 95% CI of our ERR estimates include the point estimates from pooled studies of external exposure ([@CIT0003],[@CIT0046]).

![Age dependence of the sex-averaged ERR at a thyroid dose of 1 Gy for the descriptive model (green line) and the mechanistic model (black line with gray-shaded 95% CI); for comparison the estimates of Tronko *et al.* ([@CIT0006]) (all histological types for first screening), Brenner *et al*. ([@CIT0007]) (PTC only for second to fourth screening), from CLIP2 measurements in PTCs (AaO \< 20 years) and of Jacob *et al.* ([@CIT0044]) (all histological types) for Japanese a-bomb survivors exposed at 8 years (red line with pink 95% CI) are shown.](carcin_bgw102_f0003){#F3}

### Retrospective analysis {#s16}

Applying the relation

ERR

(

D

)

=

P

mol

(

D

)

/

(

1

−

P

mol

(

D

)

)

,

which links the radiation risk to the CLIP2 dose response from molecular measurements for young patients (AaO \< 20 years) ([@CIT0016]), yields an ERR estimate of 5.2 (95% CI 2.1; 13) at 1 Gy. The relation is obtained by inverting [Supplementary Equation (19)](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online for the probability of causation. The point estimates of the ERR from our preferred descriptive and mechanistic models coincide with the upper CI of the 'molecular' CLIP2 estimate, and all three lower CI are almost equal. The point estimate from CLIP2 measurements is equal to the epidemiological estimate of Tronko *et al.* ([@CIT0006]) but CIs are markedly smaller ([Figure 3](#F3){ref-type="fig"}).

### Analysis of molecular measurements {#s17}

To assess the impact of radiation on CNAs, transcriptomic profiles, BRAFV600 mutations and RET/PTC rearrangements, we have estimated the share of path-specific cases and corresponding odds ratios in patients groups which were defined by the appearance of such molecular changes ([@CIT0018]). A detailed breakdown of the analysis which addresses each molecular alteration separately is given in the [Supplementary Tables 9 and 10](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online). Due to small case numbers, the statistical analysis can only represent trends without claiming significance.

### CNAs {#s18}

CNAs were investigated on 84 patients of the UkrAm cohort (([@CIT0018]), their Figure 2). In the present study we could only include 79 patients due to a lack of TDose10 estimates for the rest. Four CNA clusters based on similar aberration patterns were detected after a hierarchical analysis. Averaged patient data for these four clusters are given in [Supplementary Table 9](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online. Twenty cases from clusters 1.2 and 2.2 showed many CNAs. This observation coincides well with the model result of 24 cases from MSC underpinning the notion that many CNAs signify a hallmark of sporadic PTC. In clusters 1.2 and 2.2, the share of MSC cases is above the total average whereas the share of radiation-induced cases lies below. Corresponding to this observation, radiation-induced cases are overrepresented in clusters 1.1 and 2.1 where CNAs are almost absent. This is also a common feature of PTC patients below age 35 years from the The Cancer Genome Atlas (TCGA) data base ([cancergenome.nih.gov](cancergenome.nih.gov)) ([@CIT0018],[@CIT0047]). Since TCGA patients have no reported radiation history the absence of CNAs is not related to radiation in the UkrAm cases.

### Transcriptome expression {#s19}

mRNA expression data from UkrAm cases published by Abend *et al.* ([@CIT0048]) were investigated for molecular subtypes of 'RAS-like' and 'BRAF-like' PTCs that have been previously published by the TCGA consortium ([@CIT0047]). The UkrAm cases were divided into four clusters C1--C4 by applying a 59-gene signature ([@CIT0018]) and revealed a 'RAS-like', an 'intermediate RAS-BRAF', a 'BRAF-like' and a so far unknown subgroup (C4) that might have represented radiation-associated PTCs ([Supplementary Table 10](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online) ([@CIT0018]). This assumption is supported by the present analysis because the mechanistic model predicts that six out of nine cases with complete patient data from cluster C4 are radiation-induced.

### Gene mutations and rearrangements {#s20}

Moreover, only three out of eight cases harboring BRAF mutations in the 'BRAF-like' cluster are related to radiation according to the mechanistic model ([Supplementary Table 10](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online). The odds ratio of 0.65 further corresponds to a decreasing association of BRAF mutations with an increasing thyroid dose in a logistic regression analysis of the data set from Ref. ([@CIT0018]). Regression of RET/PTC rearrangements on the thyroid dose did not reveal an association suggesting an equal occurrence of this characteristic alteration in radiation-induced and sporadic PTCs ([@CIT0018]) again in line with model predictions.

Discussion {#s21}
==========

The main goal of our study was to harness biomarker information for narrowing the gap between molecular biology and radiation epidemiology. Already descriptive risk assessment benefits from the introduction of such a marker. Good accordance of the CLIP2 status determined by model predictions and measurements in [Table 2](#T2){ref-type="table"} and [Supplementary Table 7](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online, indicates carcinogenic effects of radiation already at doses below 100 mGy. For the first time, a 'molecular' ERR has been derived solely from the dose response of marker measurements by Selmansberger *et al.* ([@CIT0016]) in agreement with the epidemiological result of Tronko *et al.* ([@CIT0006]) ([Figure 3](#F3){ref-type="fig"}). The PTC cases in both studies were mostly operated before the year 2001 at a similar mean age of about 17 years.

For mechanistic risk assessment, we present a novel way to integrate molecular genetic data into a model of carcinogenesis. Our multiscale approach spans several size dimensions from point mutations to tumors. The model design is based on the property of CLIP2 as a binary radiation marker ([@CIT0014],[@CIT0015]). It features the progression of cell-based key events on the path to cancer ([@CIT0021],[@CIT0022]). Development of PTC is considered separately in a CLIP2-associated path (C2C) and a CLIP2-independent path (MSC) ([Figure 1](#F1){ref-type="fig"}).

True to its dual purpose, the model is validated with both molecular measurements and epidemiological data. It reproduces the observed dose response of CLIP2 overexpression in young patients ([Figure 2](#F2){ref-type="fig"}) ([@CIT0016]). Based on this response, model predictions on the frequency of CLIP2-positive/negative cases conform remarkably to the measured CLIP2 data from 141 PTC patients contained in the CTB ([Table 2](#T2){ref-type="table"} and [Supplementary Table 7](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online). Risk estimates are in good agreement with age and dose-dependent estimates for thyroid cancer after Chernobyl in cohorts UkrAm and BelAm, and with estimates from pooled studies of external childhood exposure ([@CIT0003],[@CIT0006],[@CIT0046]) ([Figure 3](#F3){ref-type="fig"}).

Selmansberger *et al.* ([@CIT0015]) postulated CLIP2-negative markers exclusively in unexposed patients and CLIP2-positive markers in exposed patients. Under these assumptions, a marker sensitivity of 76% and a marker specificity of 75% were found. However, the present model predictions reveal a more complex situation in [Table 2](#T2){ref-type="table"}. CLIP2-positive cases may appear in unexposed patients and CLIP2-negative cases may appear in exposed patients. Underpinned by the close agreement between measured and predicted cases, we expect a much higher reliability of the CLIP2 marker with both specificity and sensitivity closer to the optimal value of 100%. Yet more accurate estimates for both quantities are difficult to obtain. Since the model can only assign a probability for the CLIP2 status of a single PTC case the 'true' subdivision of cases according to their CLIP2 status is not available. After cross-checking with both model predictions of this study and an independent epidemiological risk estimate ([@CIT0006]), CLIP2 emerges as a radiation marker of high quality.

With the validated model, various forms of molecular changes in PTC were analyzed to obtain a more comprehensive characterization of the molecular landscape. The number of PTC cases with many CNAs is nearly reproduced by the model suggesting that CNAs mainly arise in the sporadic MSC path ([Supplementary Table 9](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online). The cumulative occurrence of CNAs on chromosomes 1p and 19 (([@CIT0018]), their Figure 2) might be related to the two or three driver gene mutations which are assumed in MSC ([Figure 1](#F1){ref-type="fig"}). The model design is further supported by the rare occurrence of genetic alterations for radiation-induced PTC via the CLIP2-associated path as postulated by Takano ([@CIT0039]) ([Supplementary Table 9](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online). Radiation effects on BRAFV600E mutations, RET/PTC rearrangements and transcriptomic changes were also investigated with the model. Its predictions look plausible by comparison with published data on UkrAm cases ([Supplementary Table 10](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online) ([@CIT0018]).

Williams ([@CIT0049]) proposed an alternative model concept which starts with thyrocytes as exclusive cells of origin for PTC. It relies on similar initial molecular changes possibly related to RET/PTC rearrangements for both sporadic and radiation-induced PTC. These early mutations are then amplified during childhood by growing cell clones in the follicular epithelium. Terminal mutations in initiated clones suppress growth limitations in young adults and give rise to well differentiated PTC later on. For radiation-induced PTC, this concept is not supported by our analysis which suggests a distinct path of CLIP2-associated carcinogenesis with its own molecular pattern and temporal development. RET/PTC rearrangements in particular do not show a dose response ([@CIT0018]) ([Table 3](#T3){ref-type="table"}). A single path model with a dose response in initial mutations was designed with the concept of Williams ([@CIT0049]). Fits of this model with eight parameters to the epidemiological data yielded a deviance about 40 points higher compared to the preferred mechanistic model.

###### 

Characterization of CLIP2-associated carcinogenesis (C2C) and MSC in papillary thyroid cancer by epidemiological covariables and molecular changes, odds ratios (OR as ratio of case shares with and without a given property) are calculated by the mechanistic model

                            CLIP2-associated carcinogenesis   Multistage carcinogenesis                                                                                                                                                                                     
  ------------------------- --------------------------------- --------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CLIP2 marker              Strong dose response              No dose response            Absent                                                                                                                                                                            Model concept^a^, [Figure 1](#F1){ref-type="fig"}
  Susceptible cells         Thyroblasts or thyrocytes^b^      Thyrocytes                  Cell no. *N* ~b~, *N* ~s~, [Supplementary Figures 1 and 2](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online   
  Pre-neoplastic lesions    Absent                            Absent                      (Probably) present                                                                                                                                                                Clonal growth γ, [Supplementary Figure 2](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online
  Share of cases^c^         54% (76 cases)                    11% (15 cases)              35% (50 cases)                                                                                                                                                                    Model result, [Supplementary Equation (21)](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online
  Share of cases^d^         56% (64 cases)                    16% (19 cases)              28% (32 cases)                                                                                                                                                                    Model result, [Supplementary Equation (21)](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online
  AaE (years)               \<5 (OR 1.8)                      ≥5 (OR 8.1)                 ≥5 (OR 1.6)                                                                                                                                                                       [Supplementary Table 11](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at Carcinogenesis Online
  TsE (years)               \<17 (OR 1.4)                     ≥17 (OR 1.8)                ≥17 (OR 1.5)                                                                                                                                                                      [Supplementary Table 11](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at Carcinogenesis Online
  AaO (years)               \<20 (OR 1.4)                     ≥20 (OR 30)                 Unspecific                                                                                                                                                                        [Supplementary Table 11](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at Carcinogenesis Online
  Thyroid dose (Gy)         ≥0.2 (OR 2.5)                     \<0.2 (OR 1.8)              \<0.2 (OR 3.3)                                                                                                                                                                    [Supplementary Table 11](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at Carcinogenesis Online
  Copy number alterations   Few                               NA^e^                       Many                                                                                                                                                                              [Supplementary Table 9](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at Carcinogenesis Online
  Transcriptomic cluster    C4^f^                             NA^e^                       C1, C2, C3^g^                                                                                                                                                                     [Supplementary Table 10](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at Carcinogenesis Online, see also Ref. (47)
  BRAF mutations            Rare                              NA^e^                       Frequent                                                                                                                                                                          [Supplementary Table 10](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at Carcinogenesis Online, see also Ref. (35)
  RET/PTC rearrangement     Present                           NA^e^                       Present                                                                                                                                                                           [Supplementary Table 10](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at Carcinogenesis Online, see also Refs. (33--35)

^a^Motivated by Selmansberger *et al.* (16).

^b^Hypothesis of Takano (39).

^c^One hundred and forty one PTC cases from Selmansberger *et al.* (16).

^d^One hundred and fifteen PTC cases from UkrAm cohort in this study.

^e^Not calculated due to expected small case numbers.

^f^C4 in Selmansberger *et al.* (18) (their online Supplementary Figure 1, novel transcriptomic profile radiation-induced) (model result).

^g^C1, C2, C3 in Selmansberger *et al.* (18): 'RAS-like' (C1), 'intermediate RAS-BRAF' (C2), 'BRAF-like' (C3).

We were able to relate different paths of PTC development to both molecular changes ([Supplementary Tables 9 and 10](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online) and epidemiological covariables ([Supplementary Table 11](http://carcin.oxfordjournals.org/lookup/suppl/doi:10.1093/carcin/bgw102/-/DC1), available at *Carcinogenesis* Online). [Table 3](#T3){ref-type="table"} summarizes the characteristic features of PTC development in young Ukrainian patients exposed below 19 years after Chernobyl or born after the accident. However, a one-to-one relation of molecular changes to model paths is not entirely supported by measurements ([@CIT0018]). The lack of full concordance reveals a weakness of the model which relies on a rigid path-specific classification. Yet in measured data a certain degree of overlap appeared.

Other limitations include the method of case ascertainment. Age at operation served as surrogate for age at onset of cancer but for some patients surgery was delayed by more than a year. We partially accounted for this uncertainty in the construction of the likelihood function which adapts prevalent and incidental cases differently. The date of fine needle aspiration for a confirmed PTC case would constitute a more accurate surrogate. But this information was not available for our study. The impact of dose uncertainties on risk estimates has not been taken into account. We expect small changes from corrected doses in the order of ten percent which have been found by Little *et al.* ([@CIT0050]) for the cohort of prevalent cases in Ref. ([@CIT0006]). It remains an open question if the present modeling approach represents general features of PTC development. This should be tested by applying the model to other cohorts such as the Japanese a-bomb survivors.

By leaving an imprint in the incidence data, CLIP2 alterations constitute a rate-limiting event. Moreover, recent analysis of the CLIP2 interaction network based on expression data from UkrAm cases suggests its involvement in fundamental oncogenic processes such as MAPK signaling, apoptosis and chromosome segregation ([@CIT0018]). Altogether, the findings from mechanistic modeling of epidemiological data and from molecular biology point to a function of CLIP2 as a driver gene in radiation-induced PTC. This result is new with respect to the recently published TCGA study which did not include radiation-associated PTCs ([@CIT0047]). But for a final answer, dedicated cell culture models are needed to demonstrate the oncogenic potential of CLIP2 overexpression.
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AaE

:   age at exposure

AaO

:   age at operation

C2C

:   CLIP2-related carcinogenesis

CNA

:   copy number alteration

CTB

:   Chernobyl tissue bank

EAR

:   excess absolute risk

ERR

:   excess relative risk

MSC

:   multistage carcinogenesis

PTC

:   papillary thyroid cancers

P~mol~

:   Probability of causation from CLIP2 measurements

P~epi~

:   Probability of causation from the present epidemiological analysis

rCSC

:   radiation-induced CLIP2-related carcinogenesis

sC2C

:   sporadic CLIP2-related carcinogenesis

TCGA

:   The Cancer Genome Atlas

TsE

:   time since exposure

UkrAm

:   Ukrainian-American
